Tried to read this on the company website and couldn't get it so in case other have had the same problem here's some news from Dec.05 . That enough DD for today, looking forward to a great week ahead.
Aethlon Medical Provides Progress Report to Wall Street
SAN DIEGO, Dec. 16, 2005 - Aethlon Medical, Inc., (OTCBB: AEMD):
Gives interim update of first human safety study of its Hemopurifier(TM)
Announces the CDC has initiated testing of Aethlon's technology as a potential treatment against the Ebola virus
Discusses the continued enhancement of its leadership team
Aethlon Medical, Inc., (OTCBB: AEMD) a pioneer in developing therapeutic devices for infectious disease, announced that its Chairman and CEO, James A. Joyce presented a company update yesterday at The New York Society of Security Analysts 9th Annual Biotech/Specialty Pharma Conference.
Aethlon's CEO provided the following updates:
Interim results of the company's first human safety study of its Hemopurifier(TM), which is designed to augment the immune response by clearing viruses and toxins from circulation, have shown no material adverse events in the first three patients treated. This is a small safety study of Hepatitis-C infected patients, in which patients were treated three times per week for four hours each day at the Apollo Hospital in New Delhi, India. The Apollo Hospital system is the largest in Asia, and forth largest in the world. Additional results will be provided upon completion of the study in the first quarter of 2006.
The company also announced that the Centers for Disease Control & Prevention (CDC), the U.S. agency at the forefront of public health efforts to prevent and control infectious diseases, has initiated early-stage testing of Aethlon's Hemopurifier(TM) as a potential treatment against the Ebola virus.
Aethlon also discussed the expansion of its leadership team as part of the transition from pure research and development to commercialization. In this regard, the company has attracted experienced talent to lead its finance and communications activities and has engaged formal representation in Washington, D.C. to help advance federal government and biodefense initiatives.
-- James Dorst, who joined Aethlon as Chief Financial
Officer, brings 20 years of senior management experience
in finance, operations, planning and business transactions
in both the public and private marketplaces. Prior to
joining Aethlon, Mr. Dorst was Vice President of Finance
and Operations for VerdiSoft Corporation, a
developmental-stage mobile-software developer recently
acquired by YAHOO, INC.
-- Jeffrey Richardson, has been appointed Senior Director,
Communications, has nearly 20 years of senior leadership
in international public relations for research-based
medical companies. Prior to joining Aethlon, Mr.
Richardson was Director, Global Public Relations for
Amgen, the world's largest biotechnology company.
-- Aethlon disclosed it has engaged McKenna Long & Aldridge
LLP to assist in obtaining government grants and
contracts. McKenna Long & Aldridge has an impressive track
record of producing results for clients in the emerging